SGLT2 inhibitor administration to two patients with diabetes mellitus with ascites due to cirrhosis
We used the sodium-glucose cotransporter 2 inhibitor, luseogliflozin in two patients with diabetes mellitus with Child–Pugh classification B cirrhosis and cirrhotic ascites. In each case, luseogliflozin was safely used for over three years and was also considered effective in reducing ascites. In on...
Saved in:
Main Authors: | Koji Nagayama, Risako Harada, Hiroshi Ajima, Sakurako Orikasa, Misaki Aoshima, Yutaka Oki |
---|---|
Format: | Article |
Language: | English |
Published: |
Bioscientifica
2025-07-01
|
Series: | Endocrinology, Diabetes & Metabolism Case Reports |
Subjects: | |
Online Access: | https://edm.bioscientifica.com/view/journals/edm/2025/3/EDM-25-0015.xml |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Parameters of the Component Composition of the Body and Their Relationship with the Development of Ascites in Liver Cirrhosis
by: Yu. O. Zharikov, et al.
Published: (2024-08-01) -
Risk of portal hypertensive complications preventable by TIPS in patients with ascites
by: Lorenz Balcar, et al.
Published: (2025-08-01) -
SGLT2 inhibitors in lupus nephritis: a multicentric study in Latin America
by: José L. Daza, et al.
Published: (2025-04-01) -
Efficacy and Safety of Ascites Treatment in Liver Cirrhosis
by: G. A. Ignatenko, et al.
Published: (2022-07-01) -
Liver function effects of SGLT2 inhibitor and GLP‐1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study)
by: Daisuke Tsuriya, et al.
Published: (2025-07-01)